EUVIMEDOpdag EUVIMED
Multizentrische StudieOpen access · CC BY-NC 4.0

A Real‐World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma

Dennis Thomas, Vanessa M McDonald, Gijo Thomas, Joy Lee iD, Li Ping Chung, Matthew Peters, Shakti D Shukla, Yuto Hamada, Erin S Harvey iD, Michael Fricker, Hayley See, Rejoy Sabin Thomas iD and 12 more

Clinical & Experimental Allergy · 2026-11 · 56 (11) · 1419-1430

DOI: 10.1111/cea.70348 ↗

At a glance

Multizentrische Studie in Clinical & Experimental Allergy, published online on 2026-05-27. Written by Dennis Thomas and 23 co-authors. Institution: College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia. Major MEDLINE topics: Asthma, Anti-Asthmatic Agents, Antibodies, Monoclonal, Humanized. Cited 1 times so far (Crossref); 53 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: AstraZeneca, GlaxoSmithKline Australia, Sanofi.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Real‐world data on benralizumab in patients with severe eosinophilic asthma–while controlling for confounding factors–is currently lacking.

Aim

This real‐world controlled multicentre study evaluated asthma outcomes in patients who received benralizumab compared with a severe asthma cohort who did not receive biologic therapy.

Methods

Two years of data from patients with severe eosinophilic asthma in the Australian Benralizumab Registry (ABenRa) and the Australasian Severe Asthma Registry (ASAR) were included in the analysis. Asthma control questionnaire‐5 (ACQ‐5) scores, asthma‐related quality of life (AQLQ) scores, maintenance oral corticosteroid (OCS) dose, annualised exacerbation rate and clinical remission (ACQ‐5 ≤ 1, with no asthma attacks or OCS use for 12 months, assessed at the 24‐month follow‐up) rates were compared between the groups after adjusting for baseline imbalances.

Results

A total of 211 participants from ABenRa (64.5% female; mean age 57.4 ± 14.5 years) and 250 from ASAR (63.1% female; mean age 53.7 ± 14.8 years) were included. ACQ and AQLQ improved significantly in both groups. Participants in the ABenRa showed greater improvements in ACQ at 12‐ (β = −0.5, p = 0.002) and 24‐months (β = −0.5, p = 0.003), as well as in AQLQ at 12‐ (β = 0.6, p < 0.001) and 24‐months (β = 0.4, p = 0.019), compared with the ASAR group, with no difference in maintenance OCS dose or annualised exacerbation rates between groups. At 12‐ and 24‐months, approximately 60% of participants in the ABenRa achieved controlled or partially controlled asthma as per the GINA guidelines. Notably, clinical benefit was evident within 14 days of initiating treatment. A higher proportion of participants in the ABenRa achieved clinical remission (30.9% vs. 20.4%; OR 2.1 (95% CI 1.1, 4.1), p = 0.037).

Conclusion

Benralizumab was associated with significant improvement in asthma outcomes in patients with severe eosinophilic asthma. This benefit persisted when compared with patients who had severe eosinophilic asthma but did not receive any biologic therapy.

Subjects

MeSH terms (MEDLINE)

AsthmaAnti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedHumansFemaleMaleMiddle AgedTreatment OutcomeAdultQuality of LifeAgedSeverity of Illness IndexRegistries

Substances

benralizumabAnti-Asthmatic AgentsAntibodies, Monoclonal, Humanized

Authors and institutions

  • College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia.
  • Centre of Excellence in Treatable Traits, Hunter Medical Research Institute, Asthma and Breathing Programme, Newcastle, New South Wales, Australia.
  • Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, New South Wales, Australia.
  • Department of Respiratory and Sleep Medicine, Austin Health, Melbourne, Victoria, Australia.
  • Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
  • Department of Thoracic Medicine, Concord Hospital, Concord, Australia.

ORCID profiles: Joy Lee, Erin S Harvey, Rejoy Sabin Thomas, Claude S Farah, Peter G Middleton

Funding

  • AstraZeneca
  • GlaxoSmithKline Australia
  • Sanofi

Cite

APA

Thomas, D., McDonald, V. M., Thomas, G., Lee, J., Chung, L. P., Peters, M., Shukla, S. D., Hamada, Y., Harvey, E. S., Fricker, M., See, H., Sabin Thomas, R., Farah, C. S., Gillman, A., Katelaris, C. H., Katsoulotos, G. P., Langton, D., Middleton, P. G., Reynolds, P., …, & Gibson, P. G. (2026). A Real‐World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma. Clinical & Experimental Allergy, 56(11), 1419-1430. https://doi.org/10.1111/cea.70348

Vancouver

Thomas D, McDonald VM, Thomas G, Lee J, Chung LP, Peters M, et al. A Real‐World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma. Clinical & Experimental Allergy. 2026;56(11):1419-1430. doi:10.1111/cea.70348

BibTeX
@article{Thomas2026,
  author = {Thomas, Dennis and McDonald, Vanessa M and Thomas, Gijo and Lee, Joy and Chung, Li Ping and Peters, Matthew and Shukla, Shakti D and Hamada, Yuto and Harvey, Erin S and Fricker, Michael and See, Hayley and Sabin Thomas, Rejoy and Farah, Claude S and Gillman, Andrew and Katelaris, Constance H and Katsoulotos, Gregory P and Langton, David and Middleton, Peter G and Reynolds, Paul and Rimmer, Janet and Thien, Francis and Vincent, Stephen and Upham, John W and Gibson, Peter G},
  title = {A Real‐World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma},
  journal = {Clinical & Experimental Allergy},
  year = {2026},
  volume = {56},
  number = {11},
  pages = {1419--1430},
  doi = {10.1111/cea.70348}
}
Start for free →